Targeting Neuroblastoma Stem Cells with Retinoic Acid and Proteasome Inhibitor

Abstract

Given that stem-like cells are associated with resistant to conventional therapy and are thought to be responsible for relapse, our results suggest that dual therapy of RA and proteasome inhibitor might be beneficial for targeting the side-population of cells associated residual disease in high-risk neuroblastoma.